CNM-Au8

HEALEY ALS Platform Trial - Master Protocol

Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and CNMAu8.EAP02 for ALS

Intermediate Expanded Access Protocol CNMAu8.EAP03

An Open-Label Extension for the Phase 2 Study in Early Symptomatic Amyotrophic Lateral Sclerosis Patients on Stable Background Therapy to Assess Bioenergetic Catalysis With CNM-Au8 to Slow Disease Progression in ALS

Intermediate Expanded Access Protocol CNMAu8.EAP04

Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS)

A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis

HEALEY ALS Platform Trial - Regimen C CNM-Au8

Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis

A Phase I SAD and MAD Clinical Trial of CNM-Au8 in Healthy Male and Female Volunteers